Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands
This invention relates to methods for administering an effective amount of a dietary or nutritional supplement composition that effectively changes the quality of the meibum lipid composition of inflamed or dysfunctional meibomian glands so as to improve or increase tear break up time, reduce tear osmolarity, and elevate the omega-3 index, while reducing or eliminating the symptoms associated with dry eye or meibomianitis. The dietary or nutritional supplement composition administered to the patient suffering from inflamed or dysfunctional meibomian glands comprises an effective amount of omega-3 fatty acids.
1. A composition consisting of a single Fatty acid for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands, wherein said fatty acid consists of omega-3 fatty acids in the triglyceride form in an amount greater than 600 mg.
2. The composition consisting of a single fatty acid for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 1 , wherein said omega-3 fatty acids comprises eicosapentaenoic acid (EPA).
3. The composition consisting of a single fatty acid for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 2 , wherein said effective amount of EPA comprises an amount between 1,600 mg and 2,500 mg.
4. The composition consisting of a single fatty acid for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 2 , wherein said effective amount of EPA comprises an amount between 1,600 mg and 1,800 mg.
5. The composition consisting of a single fatty acid for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 2 , wherein said effective amount of EPA comprises 1,680 mg.
6. The composition consisting of a single fatty acid for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 2 , wherein said effective amount of EPA comprises esterified triglyceride form.
7. The composition consisting of a single fatty acid for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 2 , wherein said effective amount of EPA comprises re-esterified triglyceride form.
8. The composition consisting of a single fatty acid for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 2 , further comprising an effective amount of docosahexaenoic acid (DHA), wherein said effective amount of DHA comprises an amount greater than 500 mg.
9. The composition consisting of a single fatty acid for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 8 , wherein said EPA and said DHA are in a 3:1 ratio.
10. The composition consisting of a single fatty acid for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 8 , wherein said effective amount of DHA comprises an amount between 500 mg and 900 mg.
11. The composition consisting of a single fatty acid for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 8 , wherein said effective amount of DHA comprises 560 mg.
12. The composition consisting of a single fatty acid for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 8 , wherein said DHA comprises the triglyceride form.
13. The composition consisting of a single fatty acid for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 8 , wherein said effective amount of DHA comprises esterified triglyceride form.
14. The composition consisting of a singer fatty acid for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 8 , wherein said effective amount of DHA comprises re-esterified triglyceride form.
15. A composition consisting of a single fatty acid for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 1 , wherein said composition further comprises between 500 IU and 2,000 IU of Vitamin D.
16. The composition consisting of a single fatty acid for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 15 , wherein said Vitamin D comprises between 600 IU and 800 IU.
17. A composition consisting of a single fatty acid for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands, said composition consisting of:
an effective amount of omega-3 fatty acids in the triglyceride form, wherein said omega-3 fatty acids include eicosapentaenoic acid (EPA) in an amount greater than 600 mg; and
an effective amount of vitamin D comprising between 600 IU and 800 IU.
18. The composition consisting of a single fatty acid for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 17 , further comprising an effective amount of docosahexaenoic acid (DHIA), wherein said effective amount of DHA comprises an amount greater than 500 mg.
19. The composition consisting of a single fatty acid for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 17 , wherein said effective amount of DHA comprises the triglyceride form.
20. The composition consisting of a single fatty acid for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 18 , wherein said EPA and said DHA are in a 3:1 ratio.